View Article

Abstract

Hypertension, a prevalent cardiovascular condition, has been recognized as a significant risk factor for various adverse health outcomes, including stroke, myocardial infarction, and renal failure. Over the decades, a plethora of antihypertensive drugs have been developed and introduced into clinical practice. This review synthesizes the current state of research and evaluation of these drugs, providing an overview of their mechanisms of action, efficacy profiles, safety considerations, and comparative effectiveness. The paper commences with a discussion on the pathophysiology of hypertension, laying the foundation for understanding the targets and mechanisms of action of antihypertensive medications. Subsequent sections delve into the classes of antihypertensive drugs, including diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, ARBs, and newer agents like mineralocorticoid receptor antagonists. For each class, the review presents pivotal clinical trials, highlighting key findings related to blood pressure reduction, cardiovascular outcomes, and adverse effects. Safety profiles, drug interactions, and considerations for monitoring are critically evaluated to provide clinicians with evidence-based guidance for optimizing therapeutic outcomes while minimizing potential harms. The review also underscores the evolving landscape of antihypertensive drug development, with a focus on emerging therapies and research directions.

Keywords

Hypertension, Clinical Evaluation Method, Clinical Practice Guidelines, Clinical Study

Reference

  1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104
  2. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European society of hypertension. J Hypertens. (2009) 27:1719–42.
  3. Lurbe E, Litwin M, Pall D, Seeman T, Stabouli S, Webb NJA, et al. Insights and implications of new blood pressure guidelines in children and adolescents. J Hypertens. (2018) 36:1456–9.
  4. pall D, Zrínyi M. Non-pharmacological treatment of hypertension. In: Lurbe E, Wühl E, editors. Hypertension in Children and Adolescents. Springer Nature Switzerland AG 2019. pp. 211–24.
  5. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatographytandem mass spectrometry (HP LC-MS/MS) urine analysis.Heart. 2014; 100:855–861.
  6. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from nonadherence to recommended therapy.Hypertens Res. 2011; 34:87–90.
  7. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant        hypertension? Assessment of adherence by toxicological urine analysis.J Hypertens.2013; 31:766–774.
  8. Brinker. S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, Das SR, Halm EA, Kaplan NM, Vongpatanasin W. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension.J Am Coll Cardiol. 2014; 63:834–835.
  9. Strauch  B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, Chytil L, Marešová V, Kurcová     I, Holaj R, Wichterle D, Widimský J. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis.J Hypertens. 2013; 31:2455–2461.
  10. Williams B, Mancia G, Spiering W, et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  11. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–980.
  12. Angeli F., Reboldi G., Verdecchia P. “From apennines to andes”: Does body mass index affect the relationship between age and blood pressure? Hypertension. 2012;60:6–7.
  13. Angeli F., Reboldi G., Verdecchia P. Hypertension around the world: New insights from developing countries. J. Hypertens. 2013;31:1358–1361.
  14. Angeli F., Reboldi G., Verdecchia P. Modernization and hypertension: Is the link changing? Hypertens. Res. 2013;36:676–678.
  15. https://www.who.int/news-room/fact sheets/detail/hypertension.Diao, D; Wright, JM; Cundiff, DK; Gueyffier, F (Aug 15, 2012). "Pharmacotherapy for mild hypertension.". The Cochrane database of systematic reviews 8: CD006742.
  16. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European society of hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. (2016) 34:1887–920.
  17. Lurbe E, Litwin M, Pall D, Seeman T, Stabouli S, Webb NJA, et al. Insights and implications of new blood pressure guidelines in children and adolescents. J Hypertens. (2018) 36:1456–9. 
  18. Páll D, Zrínyi M. Non-pharmacological treatment of hypertension. In: Lurbe E, Wühl E, editors. Hypertension in Children and Adolescents. Springer Nature Switzerland AG 2019. pp. 211–24.
  19. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Cir Res. 2015;116:1074–95.
  20. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844–6.
  21. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008.Hypertension. 2011; 57:1076–1080.
  22. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, Kalantar-Zadeh K, Jacobsen SJ. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.Mayo Clin Proc. 2013; 88:1099–1107.
  23. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatographytandem mass spectrometry (HP LC-MS/MS) urine analysis.Heart. 2014; 100:855–861.          
  24. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from nonadherence to recommended therapy.Hypertens Res. 2011; 34:87–90.
  25. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis.J            Hypertens. 013; 31:766–774.      
  26. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, Das SR, Halm EA, Kaplan NM, Vongpatanasin W. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension.J Am Coll Cardiol. 2014; 63:834–835.
  27. Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, Chytil L, Marešová V, Kurcová I, Holaj R, Wichterle D, Widimský J. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis.J Hypertens. 2013; 31:2455–2461.
  28. Whelto PK, Carey RM, Aronow WS, et al. 2017.   ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017
  29. PROGRESS Collaborative Group Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. 10.1016/S0140-6736(01)06178-5
  30. Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med 2009;2:30. 10.1186/1755-7682-2-30
  31. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011;57:2037-114. 10.1016/j.jacc.2011.01.008
  32. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol 2015;65:1998-2038. 10.1016/j.jacc.2015.02.038
  33. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691–7.
  34. 2015 Vol 82 No 2S Afr Pharm J 25ReViewConclusionHypertension is a haemodynamic                  disorder, associated with a rise in peripheral vascular resistance, that can, in turn, lead to myocardial infarction, renal f11.  Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hyper tensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
  35. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
  36. FC Twins in Cardiovascular Genetic Research. Hypertension 37, 350–356 (2001).
  37. Fagard R et al. Heritability of Conventional and Ambulatory Blood Pressures?: A Study in Twins. Hypertension 26, 919–924 (1995).
  38. Surendran P et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat. Genet 48, 1151–1161 (2016).
  39. Surendran P et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat. Genet 48, 1151–1161 (2016)
  40. Liu C et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat. Genet 48, 1162–1170 (2016).
  41. Testa MA & Simonson DC Assessment of Quality-of-Life Outcomes. N. Engl. J. Med 334, 835–840 (1996).
  42. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.
  43. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 1. overview, meta-analyses, and meta-regression analyses of ranomized trials.J Hypertens. 2014; 32:2285–2295.
  44. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.Br Med J. 2009; 338:b1665.
  45. Smulyan H, et al. Blood pressure measurement: retrospective and prospective views. Am. J. Hypertens. 2011 Jun.24(6):628–634.
  46. (Pickering et al. 2005, p. 147) See The Oscillometric Technique.
  47. P (2003-09-28). "Blood Pressure & Hypertension". Retrieved 2009-10-05.
  48. Forouzanfar, M.; Dajani, H. R.; Groza, V. Z.; Bolic, M.; Rajan, S.; Batkin, I. (2015-01-01). "Oscillometric Blood Pressure Estimation: Past, Present, and Future". IEEE Reviews in Biomedical Engineering. 8: 44–63.
  49. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P (2003).
  50. Hamzaoui O, Monnet X, Teboul JL (2013). "Pulsus paradoxus". Eur. Respir. J. 42 (6): 1696–1705.
  51. Jose J, Rao GM. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res. 2006;54:226–33.
  52. Upadhayai JB, Nangia AK, Mukhija RD, Misra M, Mohan L, Singh KK. Cutaneous reactions due to antihypertensive drugs. Indian J Dermatol. 2006;51:189–91.
  53. H, Klemetsrud T, Stokke HP, Tretlis T, Westheim A. Adverse drug reactions in current antihypertensive therapy: A general practice survey of 2586 patients in Norway. Blood Press. 1999;8:94–101
  54. AI, Dunley MC, Sweet CS. Safety and Tolarability of losartan potassium, an angiotensine II receptor antagonist compared with hydrochlorthiazide, atenolol, felodipine ER and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793–5.
  55. Higgins JP,  Thompson SG,  Deeks JJ,  Altman DG. Measuring inconsistency in meta-analyses, BMJ, 2003, vol. 327 (pg. 557-560.
  56. Waeber B,  Williams B. The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 2007, vol. 28 (pg. 1462-1536).
  57. Brenner BM,  Cooper ME,  de Zeeuw D,  Keane WF,  Mitch WE,  Parving HH,  Remuzzi G,  Snapinn SM,  Zhang Z,  Shahinfar S,  Investigators RS. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 2001, vol. 345 (pg. 861-869).
  58. Shargel L, Yu ABCApplied Biopharmaceutics and Pharmacokinetics. 3rd ed Appleton & Lange: Norwalk, CT, 1993.
  59. Ritschel WAHandbook of Basic Pharmacokinetics, Including Clinical Applications. 4th ed Drug Intelligence Publications: Hamilton, IL, 1992.
  60. Lee PID, Amidon GLPharmacokinetic Analysis: A Practical Approach. Techomic Publishing Co., Inc: Lancaster, PA, 1996.
  61. Holford NHG, Sheiner LB: Understanding the dose–effect relationship: Clinical application of pharmacokinetic–pharmacodynamic models. CIin Pharmacokinet 1981;6:429–453.
  62. Ulla Hedegaard , Jesper Hallas , Lene Vestergaard ,Ravn-Nielsen , Lene Juel Kjeldsen Research in Social and Administrative Pharmacy Volume 12, Issue 2, March–April 2016, Pages 302-318.
  63. Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure: anepidemiologist’s point of view. Pathol Biol (Paris) 1999;47:594-603.
  64. SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001;37:869-74
  65. AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560-72.
  66. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
  67. Semanik MG, Flynn JT. To screen or not to screen? The value of routine blood pressure measurement in children and adolescents.Curr Pediatr Rep. 2016; 4:6.
  68. Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, Zachariah JP, Urbina EM; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association.Hypertension. 2014; 63:1116–1135.
  69. Rosner?B, Cook?NR, Daniels?S, Falkner?B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008.?Hypertension. 2013;62(2):247–254.
  70. Din-Dzietham?R, Liu?Y, Bielo?MV, Shamsa?F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488–149.
  71. Kit?BK, Kuklina?E, Carroll?MD, Ostchega?Y, Freedman?DS, Ogden?CL. Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999-2012. JAMA Pediatr. 2015;169(3):272–279.
  72. Liberman?JN, Berger?JE, Lewis?M. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents.?Arch Pediatr Adolesc Med. 2009;163(4):357–364.
  73. Raile K, Galler A, Hofer S et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007;30:2523–8.
  74. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787–92.
  75. risks, promoting healthy life. Geneva: World Health Organization, 2002; p. 58.
  76. González-Juanatey JR, Alegría Ezquerra E, Lozano Vidal J, Llisterri Caro J, García Acuña J, González Maqueda I.Impacto de la hipertensión en las cardiopatías en España. Estudio Cardiotens 1999..Rev Esp Cardiol, 54 (2001), pp. 139-49.
  77. Al Riyami AA, Afifi MM. Hypertension in Oman: distribution and correlates. J Egypt Public Health Assoc. 2002; 77(3-4):383-407.
  78. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the Management Of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension.J Hypertens. 2018; 36:1953–2041.
  79. Stergiou GS, Palatini P, Modesti PA, Asayama K, Asmar R, Bilo G, de la Sierra A, Dolan E, Head G, Kario K, et al. Seasonal variation in blood pressure: evidence, consensus and recommendations for clinical practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability.J Hypertens. 2020; In Print.
  80. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).Eur Heart J. 2016; 37:2315–2381.
  81. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, et al. The double challenge of resistant hypertension and chronic kidney disease.Lancet. 2015; 386:1588–1598.
  82. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122:1122–1131
  83. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.N Engl J Med. 2017; 377:613–622.
  84. Vikoren L.A., Nygard O.K., Lied E., Rostrup E., Gudbrandsen O.A. A randomised study on the effects of fish protein supplement on glucose tolerance, lipids and body composition in overweight adults. Br. J. Nutr. 2013;109:648–657.
  85. Ramel A., Jonsdottir M.T., Thorsdottir I. Consumption of cod and weight loss in young overweight and obese adults on an energy reduced diet for 8-weeks. Nutr. Metab. Cardiovasc. Dis. 2009;19:690–696.
  86. Erkkila A.T., Schwab U.S., de Mello V.D.F., Lappalainen T., Mussalo H., Lehto S., Kemi V., Lamberg-Allardt C., Uusitupa M.I.J. Effects of fatty and lean fish intake on blood pressure in subjects with coronary heart disease using multiple medications. Eur. J. Nutr. 2008;47:319–328.
  87. Enari H., Takahashi Y., Kawarasaki M., Tada M., Tatsuta K. Identification of angiotensin I-converting enzyme inhibitory peptides derived from salmon muscle and their antihypertensive effect. Fish. Sci. 2008;74:911–920.
  88. Kawasaki T., Seki E., Osajima K., Yoshida M., Asada K., Matsui T., Osajima Y. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J. Hum. Hypertens. 2000;14:519–523.
  89. Sun Q., Wang B., Li Y., Sun F., Li P., Xia W., Zhou X., Li Q., Wang X., Chen J., et al. Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study. Hypertension. 2016;67:541–549.
  90. Dragnes B.T., Larsen R., Ernstsen M.H., Maehre H.K., Elvevoll E.O. Impact of processing on the taurine content in processed seafood and their corresponding unprocessed raw materials. Int. J. Food Sci. Nutr. 2008;12:1–10..

Photo
Vishavjeet Pisal
Corresponding author

Department Of Pharmacology, Ashokrao Mane Institute Of Pharmacy, Ambap-416112, India

Photo
Tejaswini Kamble
Co-author

Department Of Pharmacology, Ashokrao Mane Institute Of Pharmacy, Ambap-416112, India

Photo
Pritam Salokhe
Co-author

Department Of Pharmacology, Ashokrao Mane Institute Of Pharmacy, Ambap-416112, India

Photo
Sachin Navale
Co-author

Department Of Pharmacology, Ashokrao Mane Institute Of Pharmacy, Ambap-416112, India

Photo
Nilesh Chougule
Co-author

Department Of Pharmacology, Ashokrao Mane Institute Of Pharmacy, Ambap-416112, India

Vishavjeet Pisal*,Tejaswini Kamble,Pritam Salokhe,Sachin Navale,Nilesh Chougule, Research advance in clinical evaluation of antihypertensive Drug , Int. J. of Pharm. Sci., 2024, Vol 2, Issue 1, 526-540. https://doi.org/10.5281/zenodo.10557184

More related articles
From Powder to Pill: The Development of Sufoof-e-M...
Qazi Zaid Ahmad, Saima Aslam, Zarin Fatima, Azizur Rahman, Mohamm...
Biosimilar Drug: Current Situation ...
Jagruti Pansare, Shraddha Bhalake, Sayali Erande, Ragini Patil, ...
A Overview Of Pharmacognostical, Phytochemical, Ph...
Surya devi.M, Elakiya. V, Kalaiyarasan. S, Sathish Kumar. R, Hema...
View more
An Overview of Curcumin Loaded Niosomal Gel for Anti-Inflammatory Effect ...
Awale Sainath , Dr. Wajid Chaus, Ghalge Mahesh, Kodgire Nikita, Patel Sujan, ...
Formulation And Evaluation Of Muscle Relaxant Bath Bombs Contains Neem Oil ...
Tejas Rajendra Burile, Ruchika Ravindra Umak, Prachi Ganesh Yelne, Sachin S. Padole, Anil G. Dhawde,...
Innovative and Alternative Approaches to Urticaria Management...
Krunal K. Detholia, Mukesh B. Jadeja, Umang R. Varia, Hitesh B. Katariya, Vidhi D. Panchal, Vishal B...
View more
Download PDF
Related Articles
A Comprehensive Review of Pharmacological Interventions for Chronic Pain...
Abel sabu, Viresh. K. Chandur, A R Shabaraya, ...
Study Of Outcomes of Antiplatelet Drugs Used in The Management of Cardiovascular...
Shweta Nilamwar , Pranjali Mane, Rohan Boralkar, Dr. Ashok Giri, ...
Innovations In Fast Disintegrating Tablet Formulation Harnessing The Power Of Su...
Anusha B.H., Nagendra R., Venkatesh K., Hanumanthachar Joshi, Tanuja A . J., ...
A Review On Application And Scopes For Dosage Forms Of Cissus Quadrangularis Ext...
Rohit R. Eklare, Mahesh M. Biradar, Anita S. Chavan, Vaishnavi K. Chavhan, Anjali G. Chopade, ...
From Powder to Pill: The Development of Sufoof-e-Muhazzil into Tablet for Weigh...
Qazi Zaid Ahmad, Saima Aslam, Zarin Fatima, Azizur Rahman, Mohammad Rashid, ...
More related articles
From Powder to Pill: The Development of Sufoof-e-Muhazzil into Tablet for Weigh...
Qazi Zaid Ahmad, Saima Aslam, Zarin Fatima, Azizur Rahman, Mohammad Rashid, ...
Biosimilar Drug: Current Situation ...
Jagruti Pansare, Shraddha Bhalake, Sayali Erande, Ragini Patil, ...
A Overview Of Pharmacognostical, Phytochemical, Pharmacological Studies Of Hydra...
Surya devi.M, Elakiya. V, Kalaiyarasan. S, Sathish Kumar. R, Hemamalini. T, ...
View more
From Powder to Pill: The Development of Sufoof-e-Muhazzil into Tablet for Weigh...
Qazi Zaid Ahmad, Saima Aslam, Zarin Fatima, Azizur Rahman, Mohammad Rashid, ...
Biosimilar Drug: Current Situation ...
Jagruti Pansare, Shraddha Bhalake, Sayali Erande, Ragini Patil, ...
A Overview Of Pharmacognostical, Phytochemical, Pharmacological Studies Of Hydra...
Surya devi.M, Elakiya. V, Kalaiyarasan. S, Sathish Kumar. R, Hemamalini. T, ...
View more

Copyright © 2024 IJPS. All rights reserved